National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Niraparib (Zejula®); 1L maintenance OVCA. HTA ID: 21004

Niraparib (Zejula®) is indicated as  monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.

NCPE Assessment Process Complete
Rapid review commissioned 22/02/2021
Rapid review completed 26/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of niraparib (Zejula®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by the HSE 31/03/2021
Pre-submission consultation with Applicant 01/06/2021
Full HTA submission received from Applicant 18/10/2021
Preliminary review sent to Applicant 14/06/2022
NCPE assessment recommenced 28/07/2022
Factual accuracy check sent to Applicant 31/08/2022
NCPE assessment recommenced 07/09/2022
NCPE assessment completed 26/09/2022
NCPE assessment outcome The NCPE recommends that niraparib (Zejula®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.